RUNX1 and neoplasm: Inactivating RUNX1 mutations have been described in myeloid neoplasms including MDS and cytogenetically normal AML, thus RUNX1 can be considered a tumor suppressor in these malignancies (Harada and Harada, 2011; Schnittger et al., 2011).